Bridgepoint Group (LON:BPT) Stock Price Down 1% – What’s Next?

by · The Markets Daily

Bridgepoint Group plc (LON:BPT – Get Free Report)’s stock price traded down 1% during mid-day trading on Wednesday . The company traded as low as GBX 230.90 and last traded at GBX 233. Approximately 131,944,891 shares were traded during mid-day trading, an increase of 1,256% from the average daily volume of 9,726,907 shares. The stock had previously closed at GBX 235.40.

Analyst Ratings Changes

Separately, Citigroup lowered their price objective on shares of Bridgepoint Group from GBX 415 to GBX 395 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Bridgepoint Group currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 385.

View Our Latest Stock Report on Bridgepoint Group

Bridgepoint Group Price Performance

The company has a current ratio of 279.03, a quick ratio of 3.60 and a debt-to-equity ratio of 55.04. The stock has a fifty day simple moving average of GBX 257.67 and a two-hundred day simple moving average of GBX 260.38. The company has a market cap of £2.04 billion, a PE ratio of 47.67, a price-to-earnings-growth ratio of 0.61 and a beta of 1.37.

Bridgepoint Group Company Profile

(Get Free Report)

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.

Recommended Stories